Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
March 30, 2023 16:30 ET
|
Sutro Biopharma, Inc.
- Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with platinum resistant ovarian cancer in the second quarter - - Dr. Anne Borgman joined Sutro as Chief...
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 17, 2023 16:01 ET
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference
March 01, 2023 08:00 ET
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer
February 28, 2023 08:00 ET
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 17, 2023 16:01 ET
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
January 09, 2023 16:05 ET
|
Sutro Biopharma, Inc.
- Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and...
Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 08:00 ET
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer
December 21, 2022 08:00 ET
|
Sutro Biopharma, Inc.
- Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET - SOUTH SAN FRANCISCO, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the...
Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
December 20, 2022 16:05 ET
|
Sutro Biopharma, Inc.; Vaxcyte, Inc.
- New Agreement Provides Vaxcyte Access to Expanded Rights to Develop and Manufacture Cell-Free Extract, a Key Component of Vaxcyte's Vaccine Candidates - - Sutro to Receive $22.5 Million in...
Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022
December 10, 2022 10:30 ET
|
Sutro Biopharma, Inc.
- A total of 17 pediatric patients were treated with STRO-002 on a compassionate use basis; eight patients achieved complete remission, of which seven patients were MRD negative - - Safety and...